Black Diamond Therapeutics (BDTX) Cash from Investing Activities (2019 - 2026)

Black Diamond Therapeutics (BDTX) has 8 years of Cash from Investing Activities data on file, last reported at $19.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 128.15% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.0 million (down 186.5% YoY) and the FY2025 annual result came in at -$44.9 million, down 364.65% from the prior year.
• Cash from Investing Activities grew to $19.5 million in Q1 2026, from -$2.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $27.8 million in Q4 2024 to a low of -$59.2 million in Q2 2025.
• A 5-year average of $3.6 million and a median of $8.6 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 427.52% — and 2025, when it plunged 8093.65%.
• Tracing BDTX's Cash from Investing Activities over 5 years: stood at $2.3 million in 2022, then surged by 427.52% to $12.2 million in 2023, then surged by 126.7% to $27.8 million in 2024, then tumbled by 110.4% to -$2.9 million in 2025, then jumped by 774.97% to $19.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $19.5 million (Q1 2026), -$2.9 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.